Cambridge biotech Verastem is defending the safety record of its potential drug to treat a severe form of lung cancer after disclosing that two patients in a trial of that drug died. The disclosure by Verastem , which came in an abstract of a presentation the company plans to give at an upcoming conference, spurred a 26 percent stock drop today to an all-time low for the company of $4.92.
